Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B‐cell depleted patients with persistent COVID ‐19
Transfusion · 2024
DOI: 10.1111/trf.17737 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2024. Verfasst von Tsofia Inbar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
Patients with severe B‐cell depletion related to hematological malignancies or B‐cell targeted therapy suffer from impaired antibody responses to SARS‐CoV‐2 and are at risk for prolonged COVID‐19. In this population, COVID‐19 convalescent plasma (CCP) may provide passive immunity, enhance immune response, and promote virus neutralization. This study evaluated outcomes of B‐cell depleted patients with persistent COVID‐19 treated with CCP. Study Design and Methods This analysis included all consecutive severely B‐cell depleted patients with persistent COVID‐19, receiving CCP at Rambam between 01.2022–02.2023. Persistent COVID‐19 was defined as the presence of symptoms for ≥14 days in patients with negative SARS‐CoV‐2 nucleocapsid antibody test results.
Results
Twenty patients met inclusion criteria, 17 of whom had hematological malignancies, two suffered from rheumatoid arthritis and one had both. Twelve patients received anti‐CD‐20 treatment, one ‐ CAR‐T cells and three underwent stem cell transplantation. The median duration of COVID‐19 symptoms was 27.5 days (range 14–97); 12 patients had mild‐to‐moderate COVID‐19 and 8 had severe infection. Sixteen patients required hospitalization. The majority of patients received other COVID‐19 therapies before CCP. Within a median of two days (range 1–16) post‐infusion, 19/20 patients clinically improved. No CCP‐associated adverse events were documented. COVID‐19 symptoms recurred in 3 of the improved patients. Two patients died from COVID‐19 on days 1 and 90 following the first CCP infusion.
Discussion
In severely B‐cell depleted patients with persistent COVID‐19, CCP is safe and associated with rapid clinical improvement. This subset of immunocompromised patients could particularly benefit from CCP administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
- Blood Bank and Apheresis Unit, Rambam Health Care Campus, Haifa, Israel.
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
- Division of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.
ORCID-Profile: Tsofia Inbar
Zitieren
APA
Inbar, T., Dann, E. J., Kerner, O., & Stern, A. (2024). Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B‐cell depleted patients with persistent COVID ‐19. Transfusion. https://doi.org/10.1111/trf.17737
Vancouver
Inbar T, Dann EJ, Kerner O, Stern A. Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B‐cell depleted patients with persistent COVID ‐19. Transfusion. 2024. doi:10.1111/trf.17737
BibTeX
@article{Inbar2024,
author = {Inbar, Tsofia and Dann, Eldad J and Kerner, Omer and Stern, Anat},
title = {Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B‐cell depleted patients with persistent COVID ‐19},
journal = {Transfusion},
year = {2024},
doi = {10.1111/trf.17737}
}
EUVIMED